Skip to main content
. Author manuscript; available in PMC: 2018 Jul 16.
Published in final edited form as: Cancer Res. 2017 Jul 18;77(18):4921–4933. doi: 10.1158/0008-5472.CAN-16-3413

Figure 3. USP9X deubiquitinates Hippo components LATS, AMOT, KIBRA, and WW45 in 293 cells.

Figure 3

Expression of increasing amount of USP9X resulted in decreasing amount of endogenous ubiquitinated LATS (A), AMOT (B), exogenous Kibra (C) and WW45 (D). E, Knockdown of USP9X augmented ubiquitinated LATS2. F, Enzyme defective USP9X (Myc-USP9X-H1871A) lost the ability to protect Lats2 from ubiquitination.